Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
Are you a health professional practicing in the United States?

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Non-Clinical
Efficacy of Omadacycline or Vancomycin Combined with Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Budi
Citation #
Online Ahead of Print
Date
July 2022
Real World Evidence
Nebulized bacteriophage in a patient with refractory Mycobacterium abscessus lung disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Dedrick
Citation #
9(7): ofac194.
Date
July 2022
Real World Evidence
Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: A case series
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Duah
Citation #
S1201-9712(22)00395-2.
Date
July 2022
Microbiology
In Vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Abd El-Aziz Gadallah
Citation #
Online ahead of print
Date
July 2022
Non-Clinical
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Abbey
Citation #
Online ahead of print
Date
June 2022
Non-Clinical
Effect of Omadacycline Alone and in Combination with Meropenem Against Clinical Acinetobacter baumannii Isolates
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
O’Donnell
Citation #
29:147-149
Date
June 2022
Real World Evidence
Difficulty in diagnosis and management of musculoskeletal nontuberculous mycobacterial infections
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Vietor
Citation #
29:e01527
Date
June 2022
Microbiology
Comparison of antibacterial activities and resistance mechanisms of omadacycline and tigecycline against Enterococcus faecium
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Liu
Citation #
Online ahead of print
Date
June 2022
Review
Current Challenges in the Management of Skin and Soft Tissue Infection and Community-Acquired Pneumonia
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Lauterio
Citation #
71 (5 Suppl):S2-9
Date
June 2022
Review
Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Vacalis
Citation #
71 (5 Suppl):S10-27
Date
June 2022
Prevalence and Predictors of Pseudomonas aeruginosa among Hospitalized Patients with Diabetic Foot Infections
Resource Type
Manuscript
Areas of Interest
Diabetic Foot Infections
Author Name
Veve
Citation #
Online
Date
June 2022
Real World Evidence
A Rare Insidious Case of Skin and Soft Tissue Infection Due to Mycobacterium abscessus: A Case Report
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Cardenas
Citation #
14(6):e25725
Date
June 2022
Real World Evidence
Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
Resource Type
Manuscript
Areas of Interest
Multiple
Author Name
Morrisette
Citation #
Online ahead of print
Date
May 2022
Microbiology
In vitro Antibacterial Activity of Cefiderocol against Recent Multidrug-Resistant Carbapenem-nonsusceptible Enterobacterales Isolates
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Zhang
Citation #
103(1):115651
Date
May 2022
Real World Evidence
Host and Pathogen Response to Bacteriophage Engineered against Mycobacterium abscessus Lung Infection
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Nick
Citation #
185(11):1860-1874
Date
May 2022
Real World Evidence
Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Little
Citation #
13, 2313:1-13
Date
May 2022
Pharmacokinetics - Pharmacodynamics
Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Leviton
Citation #
42:193-197
Date
April 2022
Pharmacokinetics - Pharmacodynamics
Pharmacokinetics, Safety, and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Yang
Citation #
21;13:869237.
Date
April 2022
Non-Clinical
Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhea
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Leahy
Citation #
Online ahead of print
Date
April 2022
Pharmacokinetics - Pharmacodynamics
Omadacycline Pharmacokinetics and Soft-Tissue Penetration in Diabetic Patients with Wound Infections and Healthy Volunteers using In Vivo Microdialysis
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Gill
Citation #
77(5):1372-1378
Date
April 2022
Microbiology
Omadacycline Efficacy against Streptococcus Agalactiae Isolated in China: Correlation between Resistance and Virulence Gene and Biofilm Formation
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Li
Citation #
7636983
Date
April 2022
Non-Clinical
Omadacycline is Efficacious in the Hollow Fiber System Model of Pulmonary Mycobacterium-avium complex and is Potent at Clinically Attainable Doses
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Chapagain
Citation #
77(6):1694-1705
Date
March 2022
Microbiology
Evaluation of Neisseria gonorrhoeae Isolates Susceptibility to Tetracycline Antibiotics from 9 Provinces in China Since 2020
Resource Type
Manuscript
Areas of Interest
Sexually Transmitted Diseases
Author Name
Zhou
Citation #
15:1383-1389.
Date
March 2022
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2022
AMCP Nexus
accordio_arrow
AMCP Nexus
NACCHO
accordio_arrow
NACCHO 2022
DERM2022
accordio_arrow
DERM2022
AMSUS
accordio_arrow
AMSUS 2022
ECCMID
accordio_arrow
ECCMID 2022
CO Mycobacterium Conference
accordio_arrow
CO Mycobacterium Conference
AMCP
accordio_arrow
AMCP 2022
MAD-ID
accordio_arrow
MAD-ID 2022
ATS
accordio_arrow
ATS 2022
ASM-Microbe
accordio_arrow
ASM-Microbe
TMC Antimicrobial Stewardship
accordio_arrow
TMC Antimicrobial Stewardship 2022
2021
ECCMID
accordio_arrow
ECCMID 2021
ID Week
accordio_arrow
ID Week 2021
World Microbe Forum
accordio_arrow
World Microbe Forum 2021
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
ECCMID
accordio_arrow
ECCMID 2019
Efficacy of omadacycline in the treatment of acute bacterial skin and skin structure infections in patients with cellulitis or abscesses
Comparative In Vitro Activities of Omadacycline Against Mycoplasma genitalium
An Equivalency Study for Omadacycline Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI Broth Microdilution Method Using Rapidly Growing Non-Tuberculous Mycobacteria
Compatibility of Omadacycline with Select Parenteral Products in Simulated Y-Site Administration
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Preclinical efficacy assessment in a mouse model of pulmonary M. abscessus infection
Disseminated Mycobacterium abscessus in a Lung Transplant Patient & Experience with Omadacycline
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Real-world, Multicenter Assessment of Omadacycline Use in Patients with Nontuberculous Mycobacterial Infections
One Center's Experience with Omadacycline for the Treatment of Mycobacterium Abscessus Infections
Omadacycline in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Comorbidities
Clinical Response to Intravenous versus Oral Treatment in Patients with Acute Bacterial Skin and Skin Structure Infections
Multi-center Experience with Intravenous and Oral Omadacycline for Various Infections
Omadacycline is not a Substrate for Clinically Relevant Beta-Lactamase Enzymes
Treatment of Legionella pneumophila using Omadacycline versus Moxifloxacin: Subanalysis Results from a Phase 3 Randomized Double-Blind Multicenter Study (OPTIC)
Comparison of Healthcare Resource Utilization Among Adult Patients Treated with Omadacycline for ABSSSI or CABP in the 30 Day Pre- and Post-Omadacycline Prescription
Comparison of Healthcare Resource Utilization Among Adult Patients Treated with Omadacycline for ABSSSI or CABP in the 30 Day Pre- and Post-Omadacycline Prescription
Extreme temperature stability assessment for omadacycline tablets and intravenous vials
Omadacycline in Vitro Activity Against Bacillus anthracis
Comparison of Healthcare Resource Utilization Among Adult patients Treated with Omadacycline for ABSSSI or CABP in the 30 Day Pre- and Post-Omadacycline Prescription
Incidence of C. difficile infection (CDI) Cases by CDI-Standardized Infection Ratio (SIR) Among Centers for Medicare & Medicaid Services (CMS)-Participating Short-Term Acute Care Hospitals (ACH) Post Implementation of the Hospital-Acquired Condition Reduction Program (HAC-RP)
Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model
Omadacycline in Vitro Activity Against Bacillus Anthracis
Comparison of Healthcare Resource Utilization (HRU) Among Adult Patients Treated with Omadacycline (OMC) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) or Community-Acquired Bacterial Pneumonia (CABP) in the 30 Day Pre- and Post-OMC Prescription (Rx)
Prevalence and Predictors of P. aeruginosa among Hospitalized Patients with Diabetic Foot Infections: a Multicenter Evaluation
Activities of Omadacycline Alone and in Combination with Rifampin Against Staphylococcus aureus and Staphylococcus epidermidis in Biofilm Time Kill Analyses and a Novel In Vitro Biofilm Pharmacokinetic/Pharmacodynamic Model
Omadacycline MIC Quality Control Ranges Following CLSI M23-ED5 Multiple Laboratory Design
Molecular Characterization of Staphylococcus aureus Non-susceptible to Omadacycline and Susceptible to Legacy Tetracycline Agents
Activity of Omadacycline Against 7,000 Bacterial Isolates from the United States in the SENTRY Antimicrobial Surveillance Program (2020)
Real-World Experience with Omadacycline for MDR/XDR Gram-Negative Infections: A Multicenter Evaluation
Proactive choice of antibiotic may reduce the risk of Clostridioides difficile infection
Subinhibitory concentrations of omadacycline inhibit Staphylococcus aureus hemolytic activity in vitro
Updated Guidelines for Treatment and Prophylaxis of Yersinia pestis After Intentional Release
Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Comparative Activity of Omadacycline Against Extended-Spectrum Beta-lactamase Positive and Negative Escherichia coli and Klebsiella pneumoniae Strains Recovered from Urine Specimens
Treatment of Legionella pneumophila using Omadacycline versus Moxifloxacin: Subanalysis Results from a Phase 3 Randomized Double-Blind Multicenter Study (OPTIC)
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
In Vitro Activity of Omadacycline and Comparators against Gram-Positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
Omadacycline Pharmacokinetics: Impact of Comorbidities
Omadacycline Hepatic Safety: Integrated Analysis of Randomized Controlled Phase III Trials
Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
No items found.
No items found.
No items found.

Contact Us

In light of the COVID-19 pandemic, you may experience a busy signal when calling our Paratek Call Center. Please continue to try your call throughout the day to report adverse events and product quality complaints or obtain medical information for our products.

MSD Contact Form
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.

Medical Information
If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).
Report an Adverse Event
To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Request follow-up from a Medical Science Director
If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.